Mix Talent的动态

We are thrilled to announce that Recordati has entered into an agreement with Sanofi to acquire the global rights to Enjaymo? (sutimlimab), the only approved targeted therapy for Cold Agglutinin Disease (CAD), a rare and debilitating B-cell lymphoproliferative disorder. This acquisition strengthens our commitment to advancing treatments for rare diseases and expands our impact across North America and beyond. ?? As we grow, we are actively hiring! If you're passionate about making a difference in the rare disease space, join our talented team and be part of our journey. Explore exciting career opportunities at Recordati Rare Diseases North America. Click here: https://lnkd.in/gX7exwzb #Hiring #RareDiseases #Oncology #Recordati #Enjaymo #CAD #Biologics #HealthcareInnovation #JoinOurTeam https://lnkd.in/gwG3R6ys